Literature DB >> 9083283

Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure.

T Miyata1, Y Wada, Z Cai, Y Iida, K Horie, Y Yasuda, K Maeda, K Kurokawa, C van Ypersele de Strihou.   

Abstract

Recent studies have demonstrated a marked increase in the level of advanced glycation end products (AGEs) in the plasma, skin and amyloid fibrils of hemodialysis (HD) patients. The presence of AGEs in (beta2m) forming amyloid fibrils has been established in a previous immunochemical study relying on a monoclonal anti-AGE antibody. In the present study, Western blot analysis and immunohistochemistry reveal that the epitope recognized by this antibody is N epsilon-(carboxymethyl)lysine (CML) and that CML is one of the AGE structures present in amyloid fibrils. Thus, two AGE structures, CML and pentosidine, are now recognized in dialysis-related amyloidosis. AGE accumulation in uremia is not accounted for by elevated glucose levels. Since CML and pentosidine formation are closely linked to oxidative processes, we tested the hypothesis that a high oxidative stress enhanced AGE formation in HD patients. We focused on ascorbic acid (AA) because AA is easily oxidized under oxidative stress and its oxidized form (oxiAA) is a source of CML and pentosidine. In vitro incubation of beta2m with AA under atmospheric oxygen resulted in: (1) the rapid appearance of characteristic physicochemical properties of AGEs (brown color, fluorescence, polymerization tendency); (2) the transformation of beta2m into AGE-modified beta2m recognized by a specific monoclonal antibody; and (3) the accelerated formation of CML in beta2m and beta2m-peptide, recognized by mass spectrometry. A similar in vitro incubation of human serum albumin disclosed a parallel production of pentosidine measured by high-performance liquid chromatographic assay. In HD patients, the degree of AA oxidation, assessed as the ratio of oxiAA to total ascorbate, was more than twice as high as that of normal subjects (0.87 +/- 0.16 vs. 0.35 +/- 0.11, P < 0.0001), suggesting the presence of an increased oxidative stress. Interestingly, plasma level of oxiAA was correlated with the plasma levels of protein linked (P < 0.01, r2 = 0.25) and free (P < 0.05, r2 = 0.22) pentosidine. Altogether these results demonstrate that AGE, that is, CML and pentosidine, production is accelerated under oxidative stress, even in the absence of glucose. They suggest that, in uremia, CML and pentosidine production is determined both by an increased oxidative stress and the availability of precursors such as oxiAA. Finally, both CML and pentosidine contribute to the AGEs present in dialysis-related amyloid fibrils.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9083283     DOI: 10.1038/ki.1997.160

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  55 in total

1.  Evaluation of advanced glycation end products accumulation, using skin autofluorescence, in CKD and dialysis patients.

Authors:  Mihaela Oleniuc; Adalbert Schiller; Irina Secara; Mihai Onofriescu; Simona Hogas; Mugurel Apetrii; Dimitrie Siriopol; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2011-12-10       Impact factor: 2.370

2.  High plasma pentosidine level is accompanied with cardiovascular events in hemodialysis patients.

Authors:  Ryuichi Furuya; Hiromichi Kumagai; Toshio Miyata; Hirotaka Fukasawa; Shinsuke Isobe; Naoko Kinoshita; Akira Hishida
Journal:  Clin Exp Nephrol       Date:  2011-12-09       Impact factor: 2.801

Review 3.  Pathogenesis of diabetic nephropathy.

Authors:  Claudia van Dijk; Tomas Berl
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

4.  Identification of glucose-derived cross-linking sites in ribonuclease A.

Authors:  Zhenyu Dai; Benlian Wang; Gang Sun; Xingjun Fan; Vernon E Anderson; Vincent M Monnier
Journal:  J Proteome Res       Date:  2008-05-24       Impact factor: 4.466

5.  Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3.

Authors:  Natasha J McIntyre; Richard J Fluck; Christopher W McIntyre; Maarten W Taal
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-01       Impact factor: 8.237

6.  Paradox of circulating advanced glycation end product concentrations in patients with congestive heart failure and after heart transplantation.

Authors:  A Heidland; K Sebeková; A Frangiosa; L S De Santo; M Cirillo; F Rossi; M Cotrufo; A Perna; A Klassen; R Schinzel; N G De Santo
Journal:  Heart       Date:  2004-11       Impact factor: 5.994

Review 7.  Diabetic nephropathy: a disorder of oxygen metabolism?

Authors:  Toshio Miyata; Charles van Ypersele de Strihou
Journal:  Nat Rev Nephrol       Date:  2009-12-15       Impact factor: 28.314

8.  LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats.

Authors:  J L Figarola; S Scott; S Loera; C Tessler; P Chu; L Weiss; J Hardy; S Rahbar
Journal:  Diabetologia       Date:  2003-07-05       Impact factor: 10.122

9.  Tissue-advanced glycation end product concentration in dialysis patients.

Authors:  Natasha J McIntyre; Lindsay J Chesterton; Stephen G John; Helen J Jefferies; James O Burton; Maarten W Taal; Richard J Fluck; Christopher W McIntyre
Journal:  Clin J Am Soc Nephrol       Date:  2009-11-05       Impact factor: 8.237

10.  Simple non-invasive assessment of advanced glycation endproduct accumulation.

Authors:  R Meerwaldt; R Graaff; P H N Oomen; T P Links; J J Jager; N L Alderson; S R Thorpe; J W Baynes; R O B Gans; A J Smit
Journal:  Diabetologia       Date:  2004-07-09       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.